• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Tumor markers carbohydrate antigens CA 19-9 and CA-50 and carcinoembryonic antigen in pancreatic cancer and benign diseases of the pancreatobiliary tract.

作者信息

Harmenberg U, Wahren B, Wiechel K L

机构信息

Radiumhemmet, Karolinska Hospital, Stockholm, Sweden.

出版信息

Cancer Res. 1988 Apr 1;48(7):1985-8.

PMID:3349472
Abstract

Sera from patients with diseases in the pancreas, gallbladder, and bile duct were analyzed for the tumor markers CA 19-9, CA-50, and carcinoembryonic antigen. In particular CA 19-9 and CA-50 appear to be valuable in differentiating malignant from benign disease in these organs. Our sample of 72 patients with pancreatic cancer also indicates that CA 19-9 and CA-50 complement each other in 21% of the cases. They are also shown to be reliable for monitoring disease: following radical surgery for pancreatic cancer low levels of CA 19-9 and CA-50 were noted, while progressive rises of these tumor markers were related to disease progression.

摘要

相似文献

1
Tumor markers carbohydrate antigens CA 19-9 and CA-50 and carcinoembryonic antigen in pancreatic cancer and benign diseases of the pancreatobiliary tract.
Cancer Res. 1988 Apr 1;48(7):1985-8.
2
Estimation of carbohydrate antigen (CA) 19-9 levels in pure pancreatic juice of patients with pancreatic cancer.胰腺癌患者纯胰液中糖类抗原(CA)19-9水平的测定。
Am J Gastroenterol. 1988 Feb;83(2):126-9.
3
[Tumor markers of pancreatic cancer].[胰腺癌的肿瘤标志物]
Gan To Kagaku Ryoho. 1985 Feb;12(2):212-9.
4
[Importance of the tumor-associated antigen CA 19-9 in the differential diagnosis of pancreatic diseases].
Dtsch Med Wochenschr. 1985 Apr 19;110(16):624-8. doi: 10.1055/s-2008-1068875.
5
Evaluation of serum pancreatic enzymes, carbohydrate antigen 19-9, and carcinoembryonic antigen in various pancreatic diseases.多种胰腺疾病中血清胰酶、糖类抗原19-9及癌胚抗原的评估
Am J Gastroenterol. 1985 Aug;80(8):630-6.
6
Comparison of tumor marker CA 242 with CA 19-9 and carcinoembryonic antigen (CEA) in pancreatic cancer.胰腺癌中肿瘤标志物CA 242与CA 19-9及癌胚抗原(CEA)的比较。
Hepatogastroenterology. 2003 Sep-Oct;50(53):1669-74.
7
[Tumor markers in the diagnosis of tumors in the subhepatic area].
Vnitr Lek. 1994 Jun;40(6):350-3.
8
[Comparison between the gastrointestinal tumor antigen and the carcinoembryonic antigen in diseases of the digestive tract].[消化道肿瘤抗原与癌胚抗原在消化道疾病中的比较]
Minerva Med. 1985 Apr 14;76(16):765-70.
9
[Diagnostic usefulness and limitation of measuring pancreatic cancer associate antigen, SPan-1, in patients with pancreatic cancer].[胰腺癌患者中检测胰腺癌相关抗原SPan-1的诊断价值及局限性]
Gan To Kagaku Ryoho. 1989 Apr;16(4 Pt 2-1):1139-46.
10
[Role of carcinoembryonic antigen, carbohydrate antigen 19-9 and cytology of bile in diagnosis of biliary and pancreatic cancer].[癌胚抗原、糖类抗原19-9及胆汁细胞学检查在胆管癌和胰腺癌诊断中的作用]
Nihon Geka Gakkai Zasshi. 1991 Jun;92(6):716-21.

引用本文的文献

1
Carbohydrate Antigen 50: Values for Diagnosis and Prognostic Prediction of Intrahepatic Cholangiocarcinoma.癌抗原 50:用于诊断和预测肝内胆管癌的预后价值。
Medicina (Kaunas). 2020 Nov 16;56(11):616. doi: 10.3390/medicina56110616.
2
Tumour markers: An overview.肿瘤标志物:概述
Indian J Clin Biochem. 2007 Sep;22(2):17-31. doi: 10.1007/BF02913308.
3
Advances in biomarker research for pancreatic cancer.胰腺癌生物标志物研究进展。
Curr Pharm Des. 2012;18(17):2439-51. doi: 10.2174/13816128112092439.
4
RCAS1, a useful serum marker to predict the recurrence of cancer: two cases of cholangiocarcinoma and pancreatic cancer.
Dig Dis Sci. 2004 Oct;49(10):1654-6. doi: 10.1023/b:ddas.0000043381.87424.c3.
5
Selectin-mucin interactions as a probable molecular explanation for the association of Trousseau syndrome with mucinous adenocarcinomas.选择素-黏蛋白相互作用可能是特鲁索综合征与黏液腺癌关联的分子学解释。
J Clin Invest. 2003 Sep;112(6):853-62. doi: 10.1172/JCI18882.
6
CA 242, a new tumour marker for pancreatic cancer: a comparison with CA 19-9, CA 50 and CEA.CA 242,一种新型胰腺癌肿瘤标志物:与CA 19-9、CA 50和癌胚抗原的比较。
Br J Cancer. 1994 Sep;70(3):487-92. doi: 10.1038/bjc.1994.332.
7
Enzyme-linked PNA lectin binding assay compared with CA19-9 and CEA radioimmunoassay as a diagnostic blood test for pancreatic cancer.将酶联肽核酸凝集素结合试验与CA19-9和癌胚抗原放射免疫测定法相比较,作为胰腺癌的诊断性血液检测方法。
Br J Cancer. 1989 Jun;59(6):949-53. doi: 10.1038/bjc.1989.202.
8
Evaluation of CA19-9 serum levels for monitoring disease activity during chemotherapy of pancreatic adenocarcinoma.评估CA19-9血清水平以监测胰腺癌化疗期间的疾病活动情况。
J Cancer Res Clin Oncol. 1991;117(3):263-5. doi: 10.1007/BF01625436.
9
Sensitivity and specificity of CA242 in gastro-intestinal cancer. A comparison with CEA, CA50 and CA 19-9.CA242在胃肠道癌中的敏感性和特异性。与癌胚抗原(CEA)、CA50和CA19-9的比较。
Br J Cancer. 1992 Feb;65(2):215-21. doi: 10.1038/bjc.1992.44.